Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes
- PMID: 35172066
- PMCID: PMC8941980
- DOI: 10.1056/NEJMc2114590
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes
Conflict of interest statement
No potential conflict of interest relevant to this letter was reported.
Comment in
-
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.N Engl J Med. 2022 Feb 17;386(7):e17. doi: 10.1056/NEJMc2114590. N Engl J Med. 2022. PMID: 35172067 No abstract available.
Comment on
-
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.
References
-
- Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999;100:820–5. - PubMed
-
- Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463–91. - PubMed
-
- Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002;105:576–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical